140410 - Mezzion Pharma Co., Ltd.

140410 Summary

Biopharma

Stock Price & Overview

₩65,000 +0 (+0.00%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩65,000 ≈ US$46 · Market cap ₩2.0tn (≈ $1.4bn)

140410 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	7.9	8.6	31.7	30.7	26.7	28.6	18.9	19.1	5.6	8.8	14.9
Selling, General & Administrative	18.2	16.0	18.3	23.0	20.6	14.9	-27.8	-25.2	-17.7	-12.2	-12.6
Operating Income	-16.8	-14.3	-14.5	-23.3	-16.8	-7.5	-24.7	-21.9	-16.8	-7.2	-2.7
Finance Income	5.7	2.0	4.2	6.2	5.5	1.5	3.0	4.0	6.0	2.0	10.1
Finance Costs	27.6	0.6	1.9	2.7	1.8	3.9	-0.7	-2.9	-4.5	-7.8	-1.8
Pretax Income	-38.8	-14.5	-12.5	-35.9	-13.0	-12.8	-22.2	-20.8	-15.6	-12.8	5.2
Income Tax Expense	-3.9	4.9	0.2	—	—	—	1.0	-1.9	-0.7	0.2	0.9
Net Income	-34.9	-19.5	-12.7	-36.3	-13.6	-13.8	-23.3	-18.9	-14.9	-13.0	4.2
Total Comprehensive Income	-35.4	-18.3	-13.9	-38.2	-16.8	-11.7	-23.5	-19.2	-15.5	-12.0	4.0

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	98.0	74.0	92.1	54.0	83.9	75.6	58.9	75.1	74.0	95.9	103.1
Current Assets	45.6	41.9	74.2	45.9	64.2	60.7	51.8	70.0	70.5	94.2	97.3
Cash & Cash Equivalents	25.6	13.6	40.2	29.4	24.2	35.9	15.6	29.6	32.1	20.6	65.3
Inventories	5.3	5.4	5.7	8.8	11.8	7.0	6.0	2.4	2.7	2.4	2.1
Trade Receivables	1.1	0.9	2.3	2.6	2.4	2.6	2.9	1.8	1.7	1.2	1.1
Non-current Assets	52.4	32.1	17.9	8.1	19.8	15.0	7.0	5.0	3.5	1.7	5.7
Property, Plant & Equipment	2.5	2.5	2.9	4.2	4.9	5.9	4.9	1.2	0.9	0.2	0.7
Intangible Assets	49.1	28.4	12.9	1.6	14.2	8.2	1.6	1.6	1.6	0.3	2.5
Total Liabilities	80.8	27.9	30.7	27.8	21.1	18.8	16.0	17.7	20.9	43.1	40.5
Current Liabilities	79.6	26.7	29.6	26.1	18.5	15.5	13.5	17.7	20.5	16.5	13.7
Non-current Liabilities	1.3	1.3	1.1	1.7	2.6	3.3	2.5	0.0	0.4	26.6	26.8
Total Equity	17.2	46.1	61.4	26.2	62.8	56.8	42.8	57.3	53.2	52.8	62.5
Share Capital	15.2	15.0	14.8	13.4	4.5	4.4	4.4	4.3	4.2	4.1	4.1
Retained Earnings	-178.1	-143.1	-123.7	-111.1	-74.8	-61.2	-47.4	-24.1	-5.1	9.9	21.9

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	-16.6	-18.5	-11.0	-12.1	-15.1	-7.4	-20.9	-21.7	-13.2	-6.1	1.8
Cash from Investing Activities	1.9	-9.6	-25.6	17.4	-16.3	3.6	0.3	1.3	36.4	-36.8	-1.0
Purchase of Property, Plant & Equipment	-0.1	-0.6	-0.5	—	—	—	—	—	—	—	—
Cash from Financing Activities	26.7	0.7	47.2	-0.6	19.1	24.0	6.8	18.1	-11.3	—	—
Net Change in Cash	—	—	—	—	—	—	—	—	—	-44.7	25.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	2.2	2.0	2.1	2.1	1.7	2.0	1.9	2.3	2.3	2.2
Selling, General & Administrative	4.9	4.9	5.4	5.1	3.9	3.9	4.4	2.1	5.0	4.5
Operating Income	-4.5	-4.6	-5.1	-4.7	-3.5	-3.5	-4.0	-1.7	-4.6	-4.1
Finance Income	18.0	0.1	5.2	0.2	0.1	0.1	-3.5	-4.7	4.5	5.7
Finance Costs	5.8	0.8	26.7	0.6	0.2	0.1	-2.4	-0.0	1.3	1.6
Pretax Income	7.7	-5.3	-26.6	-5.1	-3.8	-3.3	-6.9	-6.3	-1.5	0.2
Income Tax Expense	—	—	-2.0	-2.0	-2.0	—	4.7	0.3	0.1	0.1
Net Income	7.7	-5.3	-24.6	-5.1	-1.9	-3.3	-11.6	-6.3	-1.6	0.1
Total Comprehensive Income	8.2	-3.2	-24.0	-4.2	-3.8	-3.3	-8.1	-2.2	-3.8	-4.2

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	125.2	98.9	98.0	87.9	89.1	70.8	74.0	74.2	77.5	87.7
Current Assets	58.1	38.3	45.6	43.5	52.0	35.0	41.9	50.3	56.9	67.8
Cash & Cash Equivalents	40.3	17.4	25.6	17.0	26.0	16.1	13.6	19.7	23.1	35.6
Inventories	5.3	5.2	5.3	5.4	5.4	5.4	5.4	5.5	5.5	5.7
Trade Receivables	1.0	0.9	1.1	1.1	0.9	1.1	0.9	1.4	1.1	1.1
Non-current Assets	67.2	60.6	52.4	44.4	37.1	35.8	32.1	23.9	20.6	19.9
Property, Plant & Equipment	2.2	2.4	2.5	2.3	1.8	2.4	2.5	2.8	3.0	3.1
Intangible Assets	64.2	57.5	49.1	41.1	34.2	32.4	28.4	20.3	16.6	16.1
Total Liabilities	86.2	83.4	80.8	50.5	47.9	27.6	27.9	20.5	22.4	30.0
Current Liabilities	85.1	82.3	79.6	49.4	47.0	26.3	26.7	19.5	21.5	29.0
Non-current Liabilities	1.1	1.1	1.3	1.1	0.9	1.2	1.3	0.9	0.9	1.0
Total Equity	39.0	15.5	17.2	37.3	41.2	43.3	46.1	53.8	55.1	57.7
Share Capital	15.3	15.2	15.2	15.1	15.1	15.0	15.0	15.0	14.9	14.8
Retained Earnings	-175.8	-183.5	-178.1	-153.5	-148.3	-146.5	-143.1	-131.6	-125.2	-123.7

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-4.8	-6.1	-6.8	-2.8	-3.2	-3.7	-1.4	-2.4	-13.3	-1.5
Cash from Investing Activities	-3.9	-2.9	13.0	-5.9	-10.9	5.8	-5.1	-1.9	0.9	-3.5
Cash from Financing Activities	31.4	0.7	2.1	-0.1	24.3	0.4	-0.2	0.9	-0.2	0.1

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

140410 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	7.9	-8.2%	-36.4%	-22.7%	-6.2%
Operating income	-16.8	—	—	—	—
Net income	-34.9	—	—	—	—
EPS	₩-1,141	—	—	—	—
Operating cash flow	-16.6	—	—	—	—
Shareholders' equity	17.2	-62.7%	-13.1%	-21.3%	-12.1%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

140410 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Operating margin	-212.0%	-166.0%	-45.7%	-75.9%	-63.0%	-26.3%
Net margin	-441.6%	-226.2%	-40.1%	-118.1%	-51.0%	-48.3%
Return on equity	-110.4%	-36.2%	-29.0%	-81.5%	-22.7%	-27.8%
Return on assets	-40.6%	-23.4%	-17.4%	-52.6%	-17.1%	-20.6%
Operating cash flow / revenue	-209.7%	-214.7%	-34.8%	-39.3%	-56.5%	-25.8%
Capex / revenue	1.7%	6.9%	1.7%	—	—	—

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 140410

Symbol	Last Price
310210Voronoi, Inc.	₩153,000 +3.9%
214370Caregen Co., Ltd.	₩44,500 +1.5%
347850D & D Pharmatech, Inc.	₩49,200 +1.4%
237690ST Pharm Co., Ltd.	₩101,200 +2.2%
226950Olix Pharmaceuticals, Inc.	₩95,900 +4.5%
068760Celltrion Pharm, Inc.	₩40,850 +0.0%
007390Naturecell Co., Ltd.	₩23,950 +0.2%
006280GC Biopharma Corp.	₩127,600 +0.5%
950160Kolon Tissue Gene, Inc.	₩17,100 +1.1%
039200Oscotec, Inc.	₩36,600 +1.9%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.